Enabling a four-fold increase in titer for mAb manufacturing using Syngene’s platform process

Learn how Syngene’s platform approach to mAb manufacturing helped a biopharma company achieve a four-fold increase in titer in less than a year, resulting in improved efficiency and reduced costs.

Author

Latest Blogs

Why CDMO Outsourcing is Moving Earlier in Biologics Development

Infographic showing the shift from traditional pharma outsourcing based on cost and capacity to a new-age CRDMO model focused on scientific depth, speed, supply-chain resilience, integration, and development flexibility.

The New-Age CRDMO: Rethinking Drug Development Partnerships

Flow Chemistry Approaches for Poorly Soluble Pharmaceutical Intermediates

Advanced Strategies for Handling Unstable Intermediates with Flow Chemistry

Electrochemical cell design: Turning electron transfer into a practical synthetic tool

Semi-targeted integration in cell line development supports stable clone selection and more predictable biologics development.

From Faster CLD to Smarter CMC Decisions: How Semi-Targeted Integration Changes the Biologics Game